Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Pfizer, Inc. (NYSE: PFE) scored another cancer drug victory this past week when the FDA green-lighted Besponsa, a drug that battles back against a rare and deadly type of leukemia. The approval adds yet another arrow to Pfizer's quiver of cancer treatments, and it could boost the company's sales by $1 billion, or more.
After failing a trial evaluating its use in a subset of non-Hodgkin lymphoma patients back in 2013, Besponsa was rescued from the risk of ending up in the dustbin when it delivered a decisive knock-out blow to cancer in patients diagnosed with relapsing or refractory B-cell precursor acute lymphoblastic leukemia, or ALL.
Image source: Pfizer, Inc.
Source: Fool.com
Pfizer Inc. Stock
€25.85
0.040%
With 31 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a hugely positive potential of 58.61% for Pfizer Inc. compared to the current price of 25.85 €.
